Literature DB >> 7404907

Metastases from transitional cell carcinoma of urinary bladder.

R J Babaian, D E Johnson, L Llamas, A G Ayala.   

Abstract

In 107 patients who died of metastatic transitional cell carcinoma, the most common sites for metastases at necropsy were the lymph nodes, liver, lung, bone, and adrenal gland. Metastases first were documented clinically in multiple-organ sites in one third of the patients; solitary metastases were present in only 9 patients at necropsy. The mean duration of survival for patients was thirteen months from the diagnosis of the primary tumor. The metastatic lesion(s) generally were evident clinically within eleven months of the primary diagnosis; death ensued usually within three months. Our finding that the majority of patients presented initially with high-grade tumors suggests that a high-grade lesion, regardless of its clinical stage, warrants early aggressive therapy.

Entities:  

Mesh:

Year:  1980        PMID: 7404907     DOI: 10.1016/0090-4295(80)90067-9

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  49 in total

1.  Bladder cancer metastasis to duodenum: an unusual presentation of obscure GI bleed.

Authors:  M Girotra; N Jani
Journal:  Dig Dis Sci       Date:  2010-06       Impact factor: 3.199

2.  Metastatic transitional cell carcinoma of the urinary bladder to the shoulder girdle.

Authors:  Alon Z Weizer; Shahrokh F Shariat; John L Haddad; Susan Escudier; Seth P Lerner
Journal:  Rev Urol       Date:  2002

3.  Primary squamous cell carcinoma of the ureter presenting with urinoma. A case report.

Authors:  G Toktaş; C Ergun; B Mansuroğlu; E Unlüer
Journal:  Int Urol Nephrol       Date:  1997       Impact factor: 2.370

4.  Are there any metastases to the chest in non-muscle-invasive bladder cancer patients on follow-up computed tomography?

Authors:  Hiroshi Juri; Mitsuhiro Koyama; Haruhito Azuma; Yoshifumi Narumi
Journal:  Int Urol Nephrol       Date:  2018-08-16       Impact factor: 2.370

5.  Upregulated MT1-MMP/TIMP-2 axis in the TSU-Pr1-B1/B2 model of metastatic progression in transitional cell carcinoma of the bladder.

Authors:  Christine L Chaffer; Bonnie Dopheide; Daniel R McCulloch; Allan B Lee; Jane M Moseley; Erik W Thompson; Elizabeth D Williams
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

6.  Transitional Cell Carcinoma of Urinary Bladder Manifesting as Extensive Retroperitoneal and Axillary Lymph Node Metastasis: An Extremely Rare Case Scenario Detected by 18F-Fluorodeoxyglucose Positron Emission Tomography Scan.

Authors:  Abhishek Purkayastha; Neelam Sharma; Rekha Vashisth; Braj Kishore
Journal:  Indian J Nucl Med       Date:  2017 Oct-Dec

Review 7.  Chemotherapy of advanced transitional cell carcinoma of the uroepithelium.

Authors:  F M Torti; W G Harker
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

Review 8.  Gemcitabine and radiotherapy in the treatment of brain metastases from transitional cell carcinoma of the bladder: a case report.

Authors:  Chris Protzel; Uwe Zimmermann; Elke Asse; Gerhard Kallwellis; Klaus Juergen Klebingat
Journal:  J Neurooncol       Date:  2002-04       Impact factor: 4.130

9.  Clinical prognostic factors for radical cystectomy in bladder cancer.

Authors:  Seung Hyun Jeon; Sung-Hyun Jeon; Sung-Goo Chang
Journal:  Cancer Res Treat       Date:  2005-02-28       Impact factor: 4.679

10.  Solitary brain metastases from carcinoma of the bladder.

Authors:  M Salvati; L Cervoni; E R Orlando; R Delfini
Journal:  J Neurooncol       Date:  1993-06       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.